Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Triflupromazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 6/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.95 |
| ▸ | TP53 | P04637 | 7/20 | 0.95 |
| ▸ | HTR1A | P08908 | 7/20 | 0.95 |
| ▸ | ADRA2A | P08913 | 6/20 | 0.95 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.95 |
| ▸ | DRD1 | P21728 | 6/20 | 0.95 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.95 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.95 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.95 |
| ▸ | DRD3 | P35462 | 6/20 | 0.95 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.95 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.95 |
| ▸ | THPO | P40225 | 5/20 | 0.95 |
| ▸ | MTOR | P42345 | 5/20 | 0.95 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.95 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.95 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.95 |
| ▸ | TSHR | P16473 | 4/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triflupromazine SCHEMBL32668886 | 0.98 | CYP1A2 (1.00) | CYP1A2CYP2D6TP53HTR1AADRA2A | |
| Triflupromazine SCHEMBL44085 | 0.98 | CYP1A2 (1.00) | CYP1A2CYP2D6TP53HTR1AADRA2A | |
| Triflupromazine SCHEMBL29419087 | 0.96 | LMNA (1.00) | CYP1A2CYP2D6TP53HTR1AADRA2A | |
| Triflupromazine SCHEMBL30903901 | 0.96 | LMNA (1.00) | CYP1A2CYP2D6TP53HTR1AADRA2A | |
| Triflupromazine SCHEMBL317144 | 0.96 | LMNA (1.00) | CYP1A2CYP2D6TP53HTR1AADRA2A | |
| SCHEMBL7750160 | 0.93 | TP53 (0.91) | CYP1A2CYP2D6TP53HTR1AADRA2A | |
| Triflupromazine SCHEMBL28057425 | 0.91 | CYP1A2 (0.87) | CYP1A2CYP2D6TP53HTR1AADRA2A | |
| SCHEMBL7346761 | 0.90 | TP53 (0.86) | CYP1A2CYP2D6TP53HTR1AADRA2A | |
| SCHEMBL23353457 | 0.90 | TP53 (0.85) | CYP1A2CYP2D6TP53HTR1AADRA2A | |
| Triflupromazine SCHEMBL9055400 | 0.90 | TP53 (0.85) | CYP1A2CYP2D6TP53HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170112829-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-04-27 | — | — | US | claimed |
| US-20110052723-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-03-03 | — | — | US | claimed |
| WO-2010101649-A2 | SIGMA 1 RECEPTOR INHIBITION AS A NOVEL THERAPEUTICAL APPROACH AGAINST HEPATITIS C VIRUS INFECTION | GASTAMINZA PABLO (US) | 2010-09-10 | — | — | WO | claimed |
| EP-2090311-A1 | Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-08-19 | — | — | EP | claimed |
| US-20090181976-A1 | Use of Compounds Binding to the Sigma Receptor for the Treatment of Metabolic Syndrome | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-07-16 | — | — | US | claimed |
| US-20090042898-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-02-12 | — | — | US | claimed |
| EP-1829534-A1 | Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-05 | — | — | EP | claimed |
| EP-1787679-A1 | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4062144-B1 | DEVICE FOR EXTRACTING A MOLECULE OF INTEREST FROM A SAMPLE MATRIX | JP SCIENT LIMITED (CA) | 2025-08-06 | — | — | EP | disclosed |
| US-20250135171-A1 | DEVICES, SYSTEMS, AND METHODS FOR AUTOMATED DELIVERY OF TOPICAL MEDICATION | GOULD DANIEL J (US) | 2025-05-01 | — | — | US | disclosed |
| US-20240189558-A1 | DEVICES, SYSTEMS, AND METHODS FOR DELIVERING TOPICAL MEDICATION | GOULD DANIEL J (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240189560-A1 | DEVICES, SYSTEMS, AND METHODS FOR DELIVERING TOPICAL MEDICATION | GOULD DANIEL J (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240189561-A1 | DEVICES, SYSTEMS, AND METHODS FOR DELIVERING TOPICAL MEDICATION | GOULD DANIEL J (US) | 2024-06-13 | — | — | US | disclosed |
| US-20050147692-A1 | Methods, compositions and devices for inducing stasis in tissues and organs | FRED HUTCHINSON CANCER RESEARCH CENTER | 2005-07-07 | — | — | US | disclosed |
| US-20050136125-A1 | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-23 | — | — | US | disclosed |
| WO-2005041655-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005041656-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN TISSUES AND ORGANS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005039291-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-06 | — | — | WO | disclosed |
| EP-0705298-B1 | ALBUMIN BASED HYDROGEL | BIOARTIFICIAL GEL TECHNOLOGIES INC (CA) | 2002-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050147692-A1 | Methods, compositions and devices for inducing stasis in tissues and organs | HIF1A, HIF1AN, PYGL | DRD2 2994/4885CYP1A2 1322/4885CYP2D6 2282/4885 |
| US-20050136125-A1 | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms | HSF1, HSP90AB1, HSP90AA1 | DRD2 4261/4885CYP1A2 4132/4885CYP2D6 3677/4885 |
| US-20090042898-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA | OPRM1, OPRL1, OPRK1 | DRD2 240/4885CYP1A2 3407/4885CYP2D6 3345/4885 |
| US-20090181976-A1 | Use of Compounds Binding to the Sigma Receptor for the Treatment of Metabolic Syndrome | SIGMAR1, GPR119, TMEM97 | DRD2 265/4885CYP1A2 498/4885CYP2D6 361/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | DRD2 4171/4885CYP1A2 1643/4885CYP2D6 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.